The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »
By
WilD on
April 30, 2011
Our controversial columnist Wil Dubois is back with another spicy edition of our new diabetes advice column, Ask D’Mine.
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
You know the answers you get here will be brutally honest and interesting, to say the least.
Robyn from Colorado, type 1, writes: I have traveled a lot over the years with my insulin in tow. Upon completion of each trip I always come to the…
Read more »
The new contact form we launched here recently to make it easier for people to share their thoughts and contribute ideas is bringing in some very interesting stuff. One note that caught our attention was a query from a woman named Sarah:
“I was diagnosed with type 2 diabetes in 2001. I currently am well-controlled on oral medication, but I am also fat (not, I’m sure you will agree, an unusual situation). When my endo says…
Read more »
By
AmyT on
August 23, 2010
My Spring post on the new injectable type 2 diabetes drug Victoza is in the running for one of the most-commented-ever blog posts here at the ‘Mine. Over 100 people now taking the medication have chimed in.
Victoza, for the unfamiliar, is a new once-daily form of the new-generation GLP-1 drugs that stimulate pancreas cells to release insulin in people with type 2 diabetes. It’s a head-to-head competitor with the injectable drug Byetta, and both…
Read more »
Get ready for a slew of diabetes news announcements, because the ADA’s huge annual conference starts today!
I’ll be on an airplane pretty much all day (Friday) heading out to Orlando to cover this conference live, although I must warn you: it’s quite overwhelming. Running around the 450,000 square-foot convention center trying to see every diabetes company represented in the enormous exhibit halls while hundreds of symposia and other talk sessions are happening simultaneously is…
Read more »
